Former Memphis Grizzlies fan favorite Yuki Kawamura will now be looking for his next opportunity with the Chicago Bulls ...

In this analysis, we explore the potential upside for Merck despite its short-term hurdles.

Merck KGaA has shed light on the failure in one lupus cohort, while pointing to secondary endpoint wins as proof that enpatoran still deserves a shot.

Merck & Co. won US approval for a shot that protects against RSV, the most common cause of hospitalization among infants.

The simplicity of Merck's monoclonal antibody for RSV in infants could be a plus in its competition with AstraZeneca's existing treatment.

Merck's (NYSE:MRK) top-selling drug – Keytruda's – impressive recent growth tells a compelling story, but it's one with a predictable ending. The pharmaceutical giant's remarkable performance ...

Barreling toward the loss of exclusivity on its blockbuster oncology therapy Keytruda, Merck & Co. has reportedly offered $3 billion to buy MoonLake Immunotherapeutics to add an inflammatory ...

Merck has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times reported on Monday, citing three people familiar with the matter.

When Merck & Co. | After Merck paid a hefty sum to co-develop and co-commercialize HER3-DXd, the drug has suffered notable setbacks in consecutive years.

Shuhei Yoshida warns of the dangers of subscription services for video game developers, as I stare soullessly at the five monthly bank charges for game subs.

AstraZeneca and Merck are still leading the pack when it comes to how oncologists perceive makers of cancer drugs, according to a report from ZoomRx.

Despite Merck KGaA’s lupus drug failing to prove itself against one form of the autoimmune disease, the German drugmaker has now shared the data to back up its belief that the therapy still has ...